Castle Biosciences' Founder, President and CEO Derek Maetzold Honored with Prestigious Lifetime Achievement Award by The American Business Awards®
MWN-AI** Summary
Castle Biosciences, Inc. announced that its founder, president, and CEO, Derek Maetzold, has received the prestigious Lifetime Achievement Award from The American Business Awards. This gold-level Stevie Award recognizes Maetzold's transformative leadership in the healthcare sector, particularly in the fields of molecular diagnostics and precision medicine.
Honored in the Management: Business Products Industries category, this award highlights Maetzold's significant contributions to patient care through innovative testing solutions that guide treatment decisions. The American Business Awards, also known as The Stevie Awards, received over 3,600 nominations this year alone, making this recognition a testament to Maetzold's exceptional impact within a crowded field.
Under Maetzold's leadership, Castle Biosciences evolved from a pioneering startup into a leader in the diagnostics industry, fundamentally altering how clinicians approach patient care. Frank Stokes, the company's CFO, praised Maetzold for his unique blend of scientific insight, business savvy, and dedication to enhancing patient outcomes, emphasizing the positive culture he has fostered within the organization—a culture that earned Castle a Top Workplace USA recognition for four consecutive years.
The judging process for the Stevie Awards involved more than 250 professionals, acknowledging Maetzold's outstanding career dedicated to innovation in precision medicine and showcasing his entrepreneurial spirit and strategic vision. Comments from judges highlighted his accomplishments in business growth, clinical relevance, and workplace culture at Castle Biosciences.
As the 2025 winners prepare for a gala ceremony in New York on June 10, the Stevie Awards aim to celebrate resilience and innovation in the American business landscape, with a keen focus on the substantial impact of leaders like Derek Maetzold.
MWN-AI** Analysis
Castle Biosciences, Inc. (Nasdaq: CSTL) recently celebrated a significant highlight in its leadership with Derek Maetzold receiving a Lifetime Achievement Award from the American Business Awards. This prestigious recognition underscores his transformative impact in the realms of healthcare, molecular diagnostics, and precision medicine, reflecting not only personal excellence but also the strong trajectory of the company itself.
From an investment perspective, Maetzold's leadership and the accolades received serve as credible indicators of the company’s growth potential. His unique blend of scientific knowledge and business insight has propelled Castle from a startup to a major player in diagnostic testing, particularly in oncology markers and other medical needs. Analysts should note that Castle's innovative tests are not merely incremental improvements; they represent significant advancements in patient care, which can enhance the company’s market position and long-term revenue potential.
The recognition from the Stevie Awards highlights the higher expectations and recognition for organizations committed to innovation and healthcare advancements. In an industry that increasingly focuses on precision medicine, Castle's offerings position it well ahead of competitors. Additionally, the company’s ongoing R&D initiatives signal a commitment to broadening its market reach by developing new tests for diseases with high unmet medical needs, including atopic dermatitis.
Investors should monitor Castle Biosciences closely as they will likely benefit from the momentum created by this recognition and the strategic vision set forth by Maetzold. This award augurs well for investor sentiment, and a continued focus on growth and innovation may keep stock performance strong. Therefore, for those looking to invest in the biotech space, Castle represents a compelling opportunity, especially as it continues to push boundaries in patient diagnostics and care.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Gold-level Stevie® Award recognizes Maetzold’s transformative leadership in the healthcare industry, including molecular diagnostics and precision medicine
FRIENDSWOOD, Texas, June 04, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its founder, president and chief executive officer Derek Maetzold has been awarded a distinguished Lifetime Achievement Award in the Management: Business Products Industries category in the 23 rd Annual American Business Awards.
The American Business Awards recognizes outstanding business performances in the United States. Also known as The Stevie Awards, for the Greek word meaning “crowned,” the awards are presented in three tiers, with gold representing the highest level of achievement, followed by silver and bronze. More than 3,600 nominations from organizations of all sizes were submitted this year for consideration in a wide range of categories. The 2025 winners will be honored at a gala ceremony in New York on June 10.
“Derek's vision and unwavering commitment to improving patient care have been the driving force behind Castle Biosciences' remarkable success story,” said Frank Stokes, chief financial officer of Castle Biosciences. “Under his leadership, Castle has grown from a pioneering startup to an industry leader that is fundamentally changing how clinicians care for their patients.
“What sets Derek apart is his rare combination of scientific expertise, business acumen and genuine passion for improving patient outcomes. He's built not just a successful company, but a purpose-driven organization with an extraordinary culture — as evidenced by our designation as a Top Workplace USA for four consecutive years.”
More than 250 professionals worldwide participated in the judging process to select this year’s Stevie Award winners. A sampling of judges’ comments regarding Derek’s remarkable achievements are included below:
- “Derek’s leadership stands out for both its long-term vision and consistent execution. The business growth, clinical relevance and culture he has built at Castle Biosciences reflect a clear legacy.”
- “This nomination details a remarkable career dedicated to innovation in precision medicine. The founder's entrepreneurial spirit, strategic vision and significant patient impact are clear.”
- “Derek Maetzold has transformed Castle Biosciences into a leading molecular diagnostics company. His achievements are outstanding and have set new standards in the industry.”
“Organizations across the United States continue to demonstrate resilience and innovation,” said Stevie Awards president Maggie Miller. “The 2025 Stevie winners have helped drive that success through their innovation, persistence and hard work. We congratulate all of the winners in the 2025 ABAs and look forward to celebrating their achievements during our June 10 gala event in New York.”
Details about the American Business Awards and the comprehensive list of 2025 Stevie winners are available here .
About the Stevie Awards
Stevie Awards are conferred in nine programs: the Asia-Pacific Stevie Awards, the German Stevie Awards, the Middle East & North Africa Stevie Awards, The American Business Awards ® , The International Business Awards ® , the Stevie Awards for Women in Business, the Stevie Awards for Great Employers, the Stevie Awards for Sales & Customer Service, and the Stevie Awards for Technology Excellence. Stevie Awards competitions receive more than 12,000 entries each year from organizations in more than 70 nations. Honoring organizations of all types and sizes and the people behind them, the Stevies recognize outstanding performances in the workplace worldwide. Learn more about the Stevie Awards at http://www.StevieAwards.com .
About Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors.
Castle’s current portfolio consists of tests for skin cancers, Barrett’s esophagus and uveal melanoma. Additionally, the Company has active research and development programs for tests in these and other diseases with high clinical need, including its test in development to help guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis seeking biologic treatment. To learn more, please visit www.CastleBiosciences.com and connect with us on LinkedIn , Facebook , X and Instagram .
DecisionDx-Melanoma, DecisionDx-CM Seq , i31-SLNB, i31-ROR, DecisionDx-SCC, MyPath Melanoma, TissueCypher, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UM Seq are trademarks of Castle Biosciences, Inc.
Investor Contact:
Camilla Zuckero
czuckero@castlebiosciences.com
Media Contact:
Allison Marshall
amarshall@castlebiosciences.com
Source: Castle Biosciences Inc.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/69d4d4ff-5716-401d-93ee-eccb787de1f3
FAQ**
How has Derek Maetzold's leadership style at Castle Biosciences Inc. (CSTL) contributed to its recognition with the Gold-level Stevie® Award for transformative leadership in the healthcare sector?
What specific innovations in molecular diagnostics and precision medicine has Castle Biosciences Inc. (CSTL) developed under Derek Maetzold’s guidance that have significantly impacted patient care?
Given the recent accolades for Castle Biosciences Inc. (CSTL), how does the team plan to leverage this recognition to further expand its portfolio and enhance its market position in the diagnostics industry?
In achieving the Lifetime Achievement Award, what key challenges did Derek Maetzold face in growing Castle Biosciences Inc. (CSTL) from a startup to an industry leader in precision medicine?
**MWN-AI FAQ is based on asking OpenAI questions about Castle Biosciences Inc. (NASDAQ: CSTL).
NASDAQ: CSTL
CSTL Trading
1.08% G/L:
$25.32 Last:
82,523 Volume:
$25.40 Open:
